Compare · BSX vs KMTS
BSX vs KMTS
Side-by-side comparison of Boston Scientific Corporation (BSX) and Kestra Medical Technologies Ltd. (KMTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KMTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $72.26B, about 45.8x KMTS ($1.58B).
- KMTS has been more active in the news (20 items in the past 4 weeks vs 11 for BSX).
- BSX has more recent analyst coverage (25 ratings vs 9 for KMTS).
- Company
- Boston Scientific Corporation
- Kestra Medical Technologies Ltd.
- Price
- -
- -
- Market cap
- $72.26B
- $1.58B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 11
- 20
- Recent ratings
- 25
- 9
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
- SEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily
- SEC Form 4 filed by EVP and CFO Monson Jonathan
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Director Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific Corporation
- Director Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)
- Chairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)
- SEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael
- Director Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)
Latest KMTS
- Kestra Appoints Curtis Kopf as Senior Vice President of Customer Experience
- Officer Webster Brian Daniel sold $412,180 worth of shares (15,000 units at $27.48) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 460,215 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.
- Chief Financial Officer Mahboob Vaseem sold $680,383 worth of shares (26,287 units at $25.88) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 60,609 units (SEC Form 4)
- Analyst initiated coverage on Kestra Medical Technologies with a new price target
- SEC Form 144 filed by Kestra Medical Technologies Ltd.
- Chief Commercial Officer Ford Alfred J Jr sold $151,141 worth of shares (6,275 units at $24.09), decreasing direct ownership by 6% to 99,564 units (SEC Form 4) (tax liability)
- Chief Financial Officer Mahboob Vaseem sold $172,635 worth of shares (6,995 units at $24.68) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 86,896 units (SEC Form 4) (withholding tax)
- Officer Umberger Traci S sold $86,073 worth of shares (3,580 units at $24.04), decreasing direct ownership by 2% to 195,825 units (SEC Form 4) (tax withholding)
- Officer Webster Brian Daniel sold $1,272,588 worth of shares (51,900 units at $24.52), decreasing direct ownership by 10% to 475,215 units (SEC Form 4) (withholding obligation)